GB2160201B
(en)
|
1984-06-14 |
1988-05-11 |
Wyeth John & Brother Ltd |
Quinazoline and cinnoline derivatives
|
US5123951A
(en)
|
1986-03-31 |
1992-06-23 |
Rhone-Poulenc Nederland B.V. |
Synergistic plant growth regulator compositions
|
JPS646261A
(en)
|
1987-03-31 |
1989-01-10 |
Nisshin Flour Milling Co |
4-thioquinazoline derivative, its production and antiulcer agent containing said derivative as active component
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
US5034393A
(en)
|
1989-07-27 |
1991-07-23 |
Dowelanco |
Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
|
US5238951A
(en)
|
1991-02-01 |
1993-08-24 |
E. R. Squibb & Sons, Inc. |
Heterocyclic amido prostaglandin analogs
|
DE4114733A1
(de)
|
1991-05-06 |
1992-11-12 |
Huels Chemische Werke Ag |
Verfahren zur herstellung von substituierten malonesteraniliden und malonsaeure-monoaniliden
|
US5710158A
(en)
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US5480883A
(en)
|
1991-05-10 |
1996-01-02 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US6057344A
(en)
|
1991-11-26 |
2000-05-02 |
Sepracor, Inc. |
Methods for treating hypertension, and angina using optically pure (-) amlodipine
|
US6498144B1
(en)
|
1993-10-18 |
2002-12-24 |
North Shore - Long Island Jewish Research Institute |
Use of scatter factor to enhance angiogenesis
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
GB9510757D0
(en)
|
1994-09-19 |
1995-07-19 |
Wellcome Found |
Therapeuticaly active compounds
|
TW321649B
(pl)
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
MX9709867A
(es)
|
1995-06-07 |
1998-03-31 |
Pfizer |
Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos.
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
CA2222545A1
(en)
|
1995-06-07 |
1996-12-19 |
Sugen, Inc. |
Quinazolines and pharmaceutical compositions
|
GB9514265D0
(en)
|
1995-07-13 |
1995-09-13 |
Wellcome Found |
Hetrocyclic compounds
|
US6143764A
(en)
|
1995-11-07 |
2000-11-07 |
Kirin Beer Kabushiki Kaisha |
Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
NZ325248A
(en)
|
1995-12-23 |
1999-09-29 |
Pfizer Res & Dev |
Quinoline and quinazoline compounds useful in therapy
|
CZ291386B6
(cs)
|
1996-02-13 |
2003-02-12 |
Zeneca Limited |
Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
NZ331191A
(en)
|
1996-03-05 |
2000-03-27 |
Zeneca Ltd |
4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
|
US6514971B1
(en)
|
1996-03-15 |
2003-02-04 |
Zeneca Limited |
Cinnoline derivatives and use as medicine
|
US6107300A
(en)
|
1996-03-27 |
2000-08-22 |
Dupont Pharmaceuticals |
Arylamino fused pyrimidines
|
ES2174250T5
(es)
|
1996-04-12 |
2010-04-21 |
Warner-Lambert Company Llc |
Inhibidores irreversibles de tirosina quinasas.
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
WO1998002434A1
(en)
|
1996-07-13 |
1998-01-22 |
Glaxo Group Limited |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
US5962407A
(en)
|
1996-07-26 |
1999-10-05 |
Kelly; Michael T. |
Loloatin derivatives and analogs
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
NZ334125A
(en)
|
1996-09-25 |
2000-10-27 |
Zeneca Ltd |
Quinoline derivatives inhibiting the effect of growth factors such as VEGF
|
ES2351684T3
(es)
|
1996-10-01 |
2011-02-09 |
Kyowa Hakko Kirin Co., Ltd. |
Compuestos heterocíclicos nitrogenados.
|
GB9700504D0
(en)
|
1997-01-11 |
1997-02-26 |
Pfizer Ltd |
Pharmaceutical compounds
|
GB9705361D0
(en)
|
1997-03-14 |
1997-04-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
WO1998047873A1
(fr)
|
1997-04-18 |
1998-10-29 |
Kirin Beer Kabushiki Kaisha |
Procede de production de derives de quinolone
|
DK0977737T3
(da)
|
1997-04-22 |
2004-01-26 |
Janssen Pharmaceutica Nv |
CRF-antagonistisk quino- og quinazoline
|
GB9708917D0
(en)
|
1997-05-01 |
1997-06-25 |
Pfizer Ltd |
Compounds useful in therapy
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
EP1005470B1
(en)
|
1997-08-22 |
2007-08-01 |
AstraZeneca AB |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
WO1999061428A1
(en)
|
1998-05-28 |
1999-12-02 |
Parker Hughes Institute |
Quinazolines for treating brain tumor
|
CA2339961C
(en)
|
1998-08-11 |
2009-01-20 |
Novartis Ag |
Isoquinoline derivatives with angiogenesis inhibiting activity
|
ATE292121T1
(de)
|
1998-08-21 |
2005-04-15 |
Parker Hughes Inst |
Chinazolinderivate
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
CA2343284C
(en)
|
1998-09-10 |
2008-11-18 |
Ipr-Institute For Pharmaceutical Research Ag |
Topical application products
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
DK1117659T3
(da)
|
1998-09-29 |
2004-03-22 |
Wyeth Corp |
Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser
|
PT1117653E
(pt)
|
1998-10-01 |
2003-06-30 |
Astrazeneca Ab |
Derivados de quinolina e quinazolina e sua utilizacao como inibidores de doencas mediadas pela citosina
|
FR2784030B1
(fr)
|
1998-10-02 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
|
DK1119567T3
(da)
|
1998-10-08 |
2005-07-25 |
Astrazeneca Ab |
Quinazolinderivater
|
GEP20032997B
(en)
|
1998-11-19 |
2003-06-25 |
Warner Lambert Co |
N-[4-(3-Chloro-4-Fluoro-Phenylamino)-7-(3-Morpholin-4-Yl-Propoxy)-Quinazolin-6-Yl]-crylamide, as an Irreversible Inhibitor of Tyrosine Kinases
|
NZ513006A
(en)
|
1999-01-22 |
2003-10-31 |
Kirin Brewery |
Quinoline derivatives and quinazoline derivatives
|
US7074800B1
(en)
|
1999-02-10 |
2006-07-11 |
Astrazeneca Ab |
Quinazoline derivatives as angiogenesis inhibitors
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
US6080747A
(en)
|
1999-03-05 |
2000-06-27 |
Hughes Institute |
JAK-3 inhibitors for treating allergic disorders
|
DE19911509A1
(de)
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
CA2366998A1
(en)
|
1999-03-19 |
2000-09-28 |
Mingshu Li |
Quinazoline formulations and therapeutic use thereof
|
US6258820B1
(en)
|
1999-03-19 |
2001-07-10 |
Parker Hughes Institute |
Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
|
EP1169041A2
(en)
|
1999-03-31 |
2002-01-09 |
The Procter & Gamble Company |
Use of carbamic acid derivatives for the treatment of viral infections
|
YU13200A
(sh)
|
1999-03-31 |
2002-10-18 |
Pfizer Products Inc. |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910577D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
US6126917A
(en)
|
1999-06-01 |
2000-10-03 |
Hadasit Medical Research Services And Development Ltd. |
Epidermal growth factor receptor binding compounds for positron emission tomography
|
EP1731511B1
(de)
|
1999-06-21 |
2015-08-12 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
GB9922171D0
(en)
|
1999-09-21 |
1999-11-17 |
Zeneca Ltd |
Chemical compounds
|
CZ20021009A3
(cs)
|
1999-09-21 |
2002-06-12 |
Astrazeneca Ab |
Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv
|
US6759410B1
(en)
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
CA2392554A1
(en)
|
1999-11-30 |
2001-06-28 |
Parker Hughes Institute |
Inhibitors of thrombin induced platelet aggregation
|
US20020002169A1
(en)
|
1999-12-08 |
2002-01-03 |
Griffin John H. |
Protein kinase inhibitors
|
TWI281915B
(en)
|
1999-12-24 |
2007-06-01 |
Kirin Brewery |
Quinoline and quinazoline derivatives and drugs containing the same
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
JP2003520855A
(ja)
|
2000-01-28 |
2003-07-08 |
アストラゼネカ アクチボラグ |
化学的化合物
|
US6664390B2
(en)
|
2000-02-02 |
2003-12-16 |
Warner-Lambert Company Llc |
Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
|
BR0108085A
(pt)
|
2000-02-07 |
2003-03-18 |
Abbott Gmbh & Co Kg |
Derivados de 2-benzotiazolil uréia e seu uso como inibidores da cinase protéica
|
DE122008000002I1
(de)
|
2000-02-15 |
2008-04-17 |
Sugen Inc |
Pyrrol substituierte indolin-2-on protein kinase inhibitoren
|
NZ521117A
(en)
|
2000-03-13 |
2005-02-25 |
Wyeth Corp |
Method of treating or inhibiting colonic polyps
|
US6608048B2
(en)
|
2000-03-28 |
2003-08-19 |
Wyeth Holdings |
Tricyclic protein kinase inhibitors
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
US6627634B2
(en)
|
2000-04-08 |
2003-09-30 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
CZ20023951A3
(cs)
|
2000-06-22 |
2004-01-14 |
Pfizer Products Inc. |
Substituované bicyklické deriváty pro léčení abnormálního buničného růstu
|
RU2283311C2
(ru)
|
2000-06-28 |
2006-09-10 |
Астразенека Аб |
Замещенные производные хиназолина и их применение в качестве ингибиторов
|
EP1174118A1
(de)
|
2000-06-28 |
2002-01-23 |
Cognis France S.A. |
Verwendung von Inulinen und Inulinderivaten
|
FR2811658B1
(fr)
|
2000-07-17 |
2004-07-02 |
Cfpi Nufarm |
Reacteur biologique a lit fixe immerge et procede de traitement d'effluents liquides
|
JP2002030083A
(ja)
*
|
2000-07-18 |
2002-01-29 |
Kirin Brewery Co Ltd |
N−(2−クロロ−4−{[6−メトキシ−7−(3−ピリジルメトキシ)−4−キノリル]オキシ}フェニル)−n’−プロピルウレアの二塩酸塩
|
CA2417500C
(en)
|
2000-07-28 |
2008-11-18 |
Georgetown University Medical Center |
Erbb-2 selective small molecule kinase inhibitors
|
CN100347169C
(zh)
|
2000-08-21 |
2007-11-07 |
阿斯特拉曾尼卡有限公司 |
喹唑啉衍生物
|
FR2813307B1
(fr)
|
2000-08-23 |
2002-11-08 |
Sanofi Synthelabo |
Aminoalkenylbenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant
|
US6653305B2
(en)
|
2000-08-26 |
2003-11-25 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
|
US6403580B1
(en)
|
2000-08-26 |
2002-06-11 |
Boehringer Ingelheim Pharma Kg |
Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
DE10042058A1
(de)
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
US6740651B2
(en)
|
2000-08-26 |
2004-05-25 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
JP2004511479A
(ja)
|
2000-10-13 |
2004-04-15 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
US6939866B2
(en)
|
2000-10-13 |
2005-09-06 |
Astrazeneca Ab |
Quinazoline derivatives
|
ATE399766T1
(de)
|
2000-10-20 |
2008-07-15 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische heterozyklen
|
WO2002034744A1
(en)
|
2000-10-25 |
2002-05-02 |
Astrazeneca Ab |
Quinazoline derivatives
|
US7253184B2
(en)
|
2000-11-02 |
2007-08-07 |
Astrazeneca Ab |
4-Substituted quinolines as antitumor agents
|
JP2004514718A
(ja)
|
2000-11-02 |
2004-05-20 |
アストラゼネカ アクチボラグ |
抗癌剤としての置換キノリン類
|
US7220751B2
(en)
|
2000-11-02 |
2007-05-22 |
Nippon Shinyaku Co., Ltd. |
Quinazoline derivatives and drugs
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
US6900220B2
(en)
|
2001-01-02 |
2005-05-31 |
Syntex (U.S.A.) Llc |
Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
|
GB0103046D0
(en)
|
2001-02-07 |
2001-03-21 |
Novartis Ag |
Organic Compounds
|
JP2002265365A
(ja)
|
2001-03-08 |
2002-09-18 |
Koyo Chemical Kk |
好中球機能抑制剤
|
JP4307843B2
(ja)
|
2001-04-19 |
2009-08-05 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
PL209822B1
(pl)
|
2001-04-27 |
2011-10-31 |
Kirin Pharma Kk |
Pochodna chinoliny lub chinazoliny, zawierająca ją kompozycja farmaceutyczna i zastosowanie
|
SE0101675D0
(sv)
|
2001-05-11 |
2001-05-11 |
Astrazeneca Ab |
Novel composition
|
WO2002092578A1
(en)
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO2002092579A1
(en)
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
4-anilinoquinazoline derivatives
|
WO2002092577A1
(en)
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
Quinazoline derivatives
|
US6734303B2
(en)
|
2001-05-18 |
2004-05-11 |
Pfizer Inc. |
Process for the production of quinazolines
|
DE10125432A1
(de)
|
2001-05-25 |
2002-11-28 |
Bayer Ag |
Substituierte Benzoylketone
|
US7132427B2
(en)
|
2001-06-21 |
2006-11-07 |
Ariad Pharmaceuticals, Inc. |
Quinazolines and uses thereof
|
CN100415720C
(zh)
|
2001-06-22 |
2008-09-03 |
麒麟医药株式会社 |
喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物
|
KR100397792B1
(ko)
|
2001-06-28 |
2003-09-13 |
한국과학기술연구원 |
4-(페닐아미노)-[1,4]디옥사노[2,3-g]퀴나졸린 유도체 및그의 제조방법
|
GB0118752D0
(en)
|
2001-08-01 |
2001-09-26 |
Pfizer Ltd |
Process for the production of quinazolines
|
US7229774B2
(en)
|
2001-08-02 |
2007-06-12 |
Regents Of The University Of Michigan |
Expression profile of prostate cancer
|
ES2453164T3
(es)
|
2001-08-15 |
2014-04-04 |
Pharmacia & Upjohn Company Llc |
Cristales que incluyen una sal de ácido málico de N-[2-(dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3H-indol-3-iliden)metil]-2,4-dimetil-1H-pirrol-3-carboxamida, procedimientos para su preparación y sus composiciones
|
US20030066060A1
(en)
|
2001-09-28 |
2003-04-03 |
Ford Richard L. |
Cross profile guided optimization of program execution
|
WO2003033472A1
(fr)
|
2001-10-17 |
2003-04-24 |
Kirin Beer Kabushiki Kaisha |
Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
|
WO2003037252A2
(en)
|
2001-10-30 |
2003-05-08 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
GB0126433D0
(en)
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
US7319107B2
(en)
|
2001-11-08 |
2008-01-15 |
Johnson & Johnson Consumer Companies, Inc. |
1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
|
GB0128108D0
(en)
|
2001-11-23 |
2002-01-16 |
Astrazeneca Ab |
Therapeutic use
|
CA2467573A1
(en)
|
2001-11-27 |
2003-06-19 |
Wyeth Holdings Corporation |
3-cyanoquinolines as inhibitors of egf-r and her2 kinases
|
WO2003048159A1
(en)
|
2001-12-05 |
2003-06-12 |
Astrazeneca Ab |
Quinoline derivatives
|
AU2002347359A1
(en)
|
2001-12-05 |
2003-06-17 |
Astrazeneca Ab |
Quinoline derivatives
|
GB0129099D0
(en)
|
2001-12-05 |
2002-01-23 |
Astrazeneca Ab |
Chemical compounds
|
WO2003050102A1
(en)
|
2001-12-10 |
2003-06-19 |
Aryx Therapeutics |
Novel compounds for the treatment of cardiac arrhythmia, synthesis, and methods of use
|
HUP0402662A2
(hu)
|
2001-12-12 |
2005-05-30 |
Pfizer Products Inc. |
Az E-2-metoxi-N-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]kinazolin-6-il}-allil)acetamid sói, előállításuk és rák elleni alkalmazásuk
|
BR0214499A
(pt)
|
2001-12-12 |
2005-05-10 |
Pfizer Prod Inc |
Derivados de quinazolina para o tratamento do crescimento anormal das células
|
AU2002361846A1
(en)
|
2001-12-21 |
2003-07-15 |
Bayer Pharmaceuticals Corporation |
Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
TW200301123A
(en)
|
2001-12-21 |
2003-07-01 |
Astrazeneca Uk Ltd |
New use
|
RU2323215C2
(ru)
|
2001-12-24 |
2008-04-27 |
Астразенека Аб |
Замещенные производные хиназолина как ингибиторы ауроракиназы
|
TW200406410A
(en)
|
2002-01-29 |
2004-05-01 |
Glaxo Group Ltd |
Compounds
|
US7109213B2
(en)
|
2002-01-29 |
2006-09-19 |
Glaxo Group Limited |
Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
|
ATE549329T1
(de)
|
2002-02-01 |
2012-03-15 |
Astrazeneca Ab |
Chinazoline verbindungen
|
DE10204462A1
(de)
|
2002-02-05 |
2003-08-07 |
Boehringer Ingelheim Pharma |
Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
|
TWI324597B
(en)
|
2002-03-28 |
2010-05-11 |
Astrazeneca Ab |
Quinazoline derivatives
|
DE10217689A1
(de)
|
2002-04-19 |
2003-11-13 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
|
US6693198B2
(en)
|
2002-04-22 |
2004-02-17 |
Xanthus Life Sciences, Inc. |
Amonafide salts
|
AU2003235838A1
(en)
|
2002-05-01 |
2003-11-17 |
Kirin Beer Kabushiki Kaisha |
Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
JP4703183B2
(ja)
|
2002-07-15 |
2011-06-15 |
シンフォニー エボルーション, インク. |
受容体型キナーゼモジュレーターおよびその使用方法
|
WO2004018430A1
(ja)
|
2002-08-23 |
2004-03-04 |
Kirin Beer Kabushiki Kaisha |
TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
|
GB0219746D0
(en)
|
2002-08-23 |
2002-10-02 |
Inst Of Ex Botany Ascr |
Azapurine derivatives
|
US7419984B2
(en)
|
2002-10-17 |
2008-09-02 |
Cell Therapeutics, Inc. |
Pyrimidines and uses thereof
|
ES2294317T3
(es)
|
2002-10-21 |
2008-04-01 |
Kirin Pharma Kabushiki Kaisha |
Sal de n-(2-cloro-4-((6,7-dimetoxi-4-quinolil)oxi)fenil)-n'-(5-metil-3-isoxazolil)urea de forma cristalina.
|
AU2003280599A1
(en)
|
2002-10-29 |
2004-05-25 |
Kirin Beer Kabushiki Kaisha |
QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
|
CA2503371C
(en)
|
2002-11-04 |
2011-01-11 |
Astrazeneca Ab |
Quinazoline derivatives as src tyrosine kinase inhibitors
|
US20040156869A1
(en)
|
2002-12-13 |
2004-08-12 |
Neurogen Corporation |
2-substituted quinazolin-4-ylamine analogues
|
RU2005119172A
(ru)
|
2002-12-18 |
2006-01-20 |
Пфайзер Продактс Инк. (Us) |
Производные 4-анилинхиназолина для лечения патологического роста клеток
|
US7238679B2
(en)
|
2002-12-23 |
2007-07-03 |
Ariad Pharmaceuticals, Inc. |
Heterocycles and uses thereof
|
WO2004060373A1
(ja)
|
2002-12-27 |
2004-07-22 |
Santen Pharmaceutical Co., Ltd. |
滲出型加齢黄斑変性治療剤
|
US8176532B1
(en)
|
2003-03-17 |
2012-05-08 |
Sprint Communications Company L.P. |
Secure access point for scada devices
|
AU2004221812B2
(en)
|
2003-03-19 |
2010-02-18 |
Exelixis Inc. |
Tie-2 modulators and methods of use
|
KR100559180B1
(ko)
|
2003-05-20 |
2006-03-14 |
김민서 |
조건부 거래에 따른 전자결제 방법 및 전자결제 서버
|
WO2005003140A1
(en)
|
2003-07-02 |
2005-01-13 |
Pharmacia & Upjohn Company Llc |
4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents
|
JP4750701B2
(ja)
|
2003-07-07 |
2011-08-17 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
マロンアミド誘導体
|
JP4299090B2
(ja)
*
|
2003-09-24 |
2009-07-22 |
株式会社東海理化電機製作所 |
車両用空調装置の操作装置
|
AU2004275842B2
(en)
|
2003-09-26 |
2010-09-02 |
Exelixis Inc. |
c-MET modulators and methods of use
|
ES2486240T3
(es)
|
2003-11-07 |
2014-08-18 |
Novartis Ag |
Sales de lactato de compuestos de quinolinona y su uso farmacéutico
|
PL1698623T3
(pl)
|
2003-12-25 |
2015-08-31 |
Eisai R&D Man Co Ltd |
Postać krystaliczna soli 4-(3-chloro-4-(cyklopropyloaminokarbonylo)aminofenoksy)-7-metoksy-6-chinolinokarboksamidu lub jej solwatu i sposoby ich wytwarzania
|
EP1711495A2
(en)
|
2004-01-23 |
2006-10-18 |
Amgen Inc. |
Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
|
AR047530A1
(es)
|
2004-02-04 |
2006-01-25 |
Novartis Ag |
Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
|
US20060030602A1
(en)
|
2004-03-16 |
2006-02-09 |
Sepracor Inc. |
(S)-amlodipine malate
|
US20050288290A1
(en)
|
2004-06-28 |
2005-12-29 |
Borzilleri Robert M |
Fused heterocyclic kinase inhibitors
|
JP5368701B2
(ja)
*
|
2004-07-02 |
2013-12-18 |
エクセリクシス、インコーポレイテッド |
c−Metモジュレーター及び使用方法
|
EP1853968A2
(en)
*
|
2005-03-04 |
2007-11-14 |
Colorlink, Inc. |
Four panel projection system
|
EP1874759A4
(en)
|
2005-04-06 |
2009-07-15 |
Exelixis Inc |
C-MET MODULATORS MODULATORS AND METHODS OF USE
|
US20080298657A1
(en)
|
2005-11-23 |
2008-12-04 |
Junji Shiraishi |
Computer-Aided Method for Detection of Interval Changes in Successive Whole-Body Bone Scans and Related Computer Program Program Product and System
|
WO2007102074A2
(en)
|
2006-03-07 |
2007-09-13 |
Cadila Healthcare Limited |
Salts of quetiapine
|
MX2008011220A
(es)
|
2006-03-07 |
2008-09-11 |
Array Biopharma Inc |
Compuestos de pirazol heterobiciclicos y metodos de uso.
|
WO2007109799A2
(en)
|
2006-03-23 |
2007-09-27 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of eszopiclone malate
|
US20080004273A1
(en)
|
2006-05-30 |
2008-01-03 |
Stephane Raeppel |
Inhibitors of protein tyrosine kinase activity
|
EP2062886B1
(en)
|
2006-08-23 |
2011-11-30 |
Eisai R&D Management Co., Ltd. |
Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
|
WO2008070616A2
(en)
|
2006-12-01 |
2008-06-12 |
University Of Utah Research Foundation |
METHODS AND COMPOSITIONS RELATED TO HIF-1α
|
JP5311673B2
(ja)
|
2006-12-14 |
2013-10-09 |
エグゼリクシス, インコーポレイテッド |
Mek阻害剤の使用方法
|
US20080200515A1
(en)
|
2006-12-29 |
2008-08-21 |
Tap Pharmaceutical Products Inc. |
Solid state forms of enantiopure ilaprazole
|
CA2747000C
(en)
|
2007-12-19 |
2013-09-03 |
Sunovion Pharmaceuticals Inc. |
Maleate, besylate, and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
|
UY31800A
(es)
|
2008-05-05 |
2009-11-10 |
Smithkline Beckman Corp |
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
|
TW201035017A
(en)
|
2008-09-26 |
2010-10-01 |
Smithkline Beecham Corp |
Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide
|
CA2738583A1
(en)
|
2008-10-01 |
2010-04-08 |
Ludwig Institute For Cancer Research |
Methods for the treatment of cancer
|
WO2010056960A1
(en)
|
2008-11-13 |
2010-05-20 |
Exelixis Inc. |
Methods of preparing quinoline derivatives
|
WO2010065838A1
(en)
|
2008-12-04 |
2010-06-10 |
Exelixis, Inc. |
Methods of preparing quinoline derivatives
|
KR20210151988A
(ko)
*
|
2009-01-16 |
2021-12-14 |
엑셀리시스, 인코포레이티드 |
암의 치료를 위한 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
|
AU2010274012A1
(en)
|
2009-07-17 |
2012-02-09 |
Exelixis, Inc. |
Crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy] -quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
WO2011031840A1
(en)
|
2009-09-09 |
2011-03-17 |
Quintiles Transnational Corp. |
Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
|
MX2012010506A
(es)
|
2010-03-12 |
2012-10-15 |
Exelixis Inc |
Formas cristalinas hidratadas del n-[3-fluoro-4-({6-(metiloxi)-7-[ (3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida.
|
US20120070368A1
(en)
|
2010-04-16 |
2012-03-22 |
Exelixis, Inc. |
Methods of Using C-Met Modulators
|
CN114209699A
(zh)
|
2010-07-16 |
2022-03-22 |
埃克塞里艾克西斯公司 |
C-met调节剂药物组合物
|
KR20210010671A
(ko)
|
2011-02-10 |
2021-01-27 |
엑셀리시스, 인코포레이티드 |
퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
EP3275443A1
(en)
|
2011-09-22 |
2018-01-31 |
Exelixis, Inc. |
Method for treating osteoporosis
|
JP2015515988A
(ja)
|
2012-05-02 |
2015-06-04 |
エクセリクシス, インク. |
溶骨性骨転移を治療するためのmet−vegf二重調節剤
|
CN114129566A
(zh)
|
2012-09-07 |
2022-03-04 |
埃克塞里艾克西斯公司 |
用于治疗肺腺癌的met、vegfr和ret的抑制剂
|
KR20150138268A
(ko)
|
2013-04-04 |
2015-12-09 |
엑셀리시스, 인코포레이티드 |
암을 치료하기 위한 약물 병용요법
|
WO2015142928A1
(en)
|
2014-03-17 |
2015-09-24 |
Exelixis, Inc. |
Dosing of cabozantinib formulations
|